Ex-Novo Nordisk protégé Schultz becomes Lundbeck CEO
This article was originally published in Scrip
Executive Summary
After a dramatic exit from Novo Nordisk last week, its former COO Kåre Schultz has been named CEO of Lundbeck.
You may also be interested in...
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.